datetime,headline,summary,url,source,sentiment,confidence
2025-04-09 12:04:27,Goldman Sachs Upgrades Johnson & Johnson (JNJ),,https://finnhub.io/api/news?id=7117b90dd0fb3487881bf2948e28a1e142f83e8b8542dc4f1e32cc1f901d011a,Fintel,positive,0.9374
2025-04-09 07:00:00,ClearBridge Value Strategy Q1 2025 Commentary,,https://finnhub.io/api/news?id=35535e3cea80b09456684a0cb073c03b1717d2f8f368e5df3aa2bd24396ed4a2,SeekingAlpha,positive,0.9235
2025-04-08 22:14:16,Johnson & Johnson (JNJ): Among Defensive Stocks Billionaire Ken Fisher is Betting On,"We recently published a list of 10 Defensive Stocks Billionaire Ken Fisher is Betting On. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other defensive stocks billionaire Ken Fisher is betting on. Ken Fisher, an American billionaire investor, author, and financial analyst, founded and runs Fisher Asset […]",https://finnhub.io/api/news?id=5a61632c3ef9b67852b1a7711606d09ff729b9975cd6925cae98ba75b3994261,Yahoo,positive,0.8973
2025-04-08 21:45:16,Johnson & Johnson (JNJ) Stock Moves -0.52%: What You Should Know,"In the latest trading session, Johnson & Johnson (JNJ) closed at $149.83, marking a -0.52% move from the previous day.",https://finnhub.io/api/news?id=ad787759b84fc77476cdb04c6f417ab65449c9324249c4dd3831a4c7926d9e61,Yahoo,positive,0.8668
2025-04-08 18:26:32,Johnson & Johnson's New 'Compelling Data' Shows Sustained Symptom Improvement In Muscular Disease Patients,"Johnson & Johnson (NYSE:JNJ) on Tuesday announced results from additional analyses of the Phase 3 Vivacity-MG3 study and the ongoing open-label extension (OLE), evaluating the long-term efficacy and safety of nipocalimab in a broad population of antibody-positive adults with generalized myasthenia gravis (gMG). Patients treated with nipocalimab plus standard of care (SOC) maintained improvements in their MG-ADL (activities of daily living) and QMG (quantifies disease severity) scores over 84 wee",https://finnhub.io/api/news?id=fdbcc6609708525d9145c5fa5b1c4c4d25fed64fa05f630967f397baf5264263,Yahoo,negative,0.9558
2025-04-08 17:58:13,"Biopharma Shakeup: Goldman Boosts J&J, Eli Lilly While Flagging Risks at Pfizer and AbbVie","Goldman updates coverage across major U.S. drugmakers, citing exclusivity risks, pricing power, and pipeline outlooks",https://finnhub.io/api/news?id=bc94276900cad2ebcc0b80e6d2292450595274f18897df2b28b0da16be1a544f,Yahoo,negative,0.7767
2025-04-08 17:44:40,"AAN 2025: J&J reveals data for nipocalimab, showing long-term disease control in MG","J&J exhibited additional findings from the Vivacity-MG3 study, displaying that nipocalimab met its key secondary endpoint.",https://finnhub.io/api/news?id=89f3d9fbbafc9265334924a2ea74638362c0539828fd0a90d48d44101500ac5c,Yahoo,negative,0.5099
2025-04-08 14:03:18,"Walgreens, CVS, & US drugmakers make big moves: What to know","Walgreens (WBA) stock is rising after the company reported better-than-expected second quarter earnings while preparing for privatization. Yahoo Finance Senior Health Reporter Anjalee Khemlani highlights the company's cost management strategy, CVS's (CVS) leadership changes amid similar challenges in the retail drug sector, and moves by US drug makers, like Merck (MRK), Johnson & Johnson (JNJ), and Eli Lilly (LLY), as they prepare for incoming tariffs. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",https://finnhub.io/api/news?id=4802859d758f4365de19e8df750d7be4ad395ac3a31a609b767e157d6ab882c0,Yahoo,positive,0.9256
2025-04-08 14:00:09,Johnson & Johnson (JNJ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?,Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,https://finnhub.io/api/news?id=6eeb98fe7b73854d0c1bd50c3826ea6f109706e5d53c42bb3f0e4d4d25279b55,Yahoo,negative,0.9356
2025-04-08 09:57:30,J&J starts IVL trial in ‘difficult-to-cross’ coronary arteries,"The device is differentiated from other Shockwave products, and rival catheters from Abbott and Boston Scientific, because it emits waves from its tip.",https://finnhub.io/api/news?id=dd2af907c5b79bd4f6a2faa7a67cdefa64ad35ff39af45cb97de991d2fcc5a2e,Yahoo,positive,0.6381
2025-04-08 09:30:34,Johnson & Johnson Says New Data Support Nipocalimab's Long-Term Disease Control in Myasthenia Gravis,Johnson & Johnson (JNJ) said Tuesday that the latest results from a trial of the investigational nip,https://finnhub.io/api/news?id=064b6b6b5d577c038bec940bbbd00b717b39c41c62018cff574c62346615c3ed,Yahoo,negative,0.9529
2025-04-08 08:50:23,EC approves extension of indication for Janssen-Cilag’s Darzalex,The approval follows October 2024's indication extension for daratumumab-VRd for newly diagnosed patients eligible for ASCT.,https://finnhub.io/api/news?id=b014ff7ef8a01915d7a7813fc02432739b08bf685536455d3f9e0ab070049f64,Yahoo,negative,0.7423
2025-04-08 07:00:00,"Johnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia gravis (gMG)","Johnson & Johnson (NYSE: JNJ) today announced results from additional analyses of the Phase 3 Vivacity-MG3 double-blind study and the ongoing open-label extensiona (OLE), evaluating the long-term efficacy and safety of investigational nipocalimab in a broad population of antibody-positive (anti-AChR+, anti-MuSK+, anti-LRP4+) adults with generalized myasthenia gravis (gMG).1,2 Patients treated with nipocalimab plus standard of care (SOC) maintained improvements in their MG-ADLc and QMGb scores ov",https://finnhub.io/api/news?id=7ea48e0f7766e6ae7c1e15376a5b5bae1d67b9ac019b0586de7f8e6daf6eb7cf,Yahoo,negative,0.8883
2025-04-07 11:12:09,J&J’s psoriatic arthritis therapy trial meets endpoints,The trial involved biologic-naïve subjects who had not responded adequately to standard therapies.,https://finnhub.io/api/news?id=d067fa015d1d667e29b308fe1b16f7e8429e177736dee6d37e7d5159aa60117c,Yahoo,positive,0.8518
2025-04-07 10:46:00,"Dow's 675-point fall led by losses for Nike, Home Depot shares","Dow's 675-point fall led by losses for Nike, Home Depot shares",https://finnhub.io/api/news?id=21f7e6db04ac2d0313d5eedcd1de78dd786ff5d88ff8f33f73f9d760c1bf6583,MarketWatch,neutral,0.9439
2025-04-07 09:27:05,Book Review: 'No More Tears' scrutinizes the legacy of health giant Johnson & Johnson,"Health care giant Johnson & Johnson is one of the most well-known and respected brands, and its response to the 1982 tampering of Tylenol bottles that killed seven people is held up in business...",https://finnhub.io/api/news?id=93347a5e560eae703295e92a4c6f301380453a9b7cad9121d99dc4ac17b9e247,Finnhub,positive,0.8782
2025-04-07 08:00:00,ClearBridge Small Cap Growth Strategy Q1 2025 Commentary,,https://finnhub.io/api/news?id=0d05ee80576887f8a527e6fc394b8892dec4c03a3e0052f0f59e58bc6ee0b379,SeekingAlpha,positive,0.8695
2025-04-07 07:03:15,Johnson & Johnson - TREMFYA is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis,SPRING HOUSE - Johnson & Johnson today announced that the TREMFYA Phase 3b APEX study achieved both its primary endpoint of reducing signs and symptoms and its major secondary endpoint of reducing...,https://finnhub.io/api/news?id=558d01e114dcdcaafaade42cf2f1496d96fde0df6af51d4fc736ebb2c947d1de,Finnhub,negative,0.8516
2025-04-05 19:00:00,Tariffs Stoke Fears That Hung Debt Will Return,"(Bloomberg) -- Deals in leveraged finance have stalled, and markets have been upended, raising the possibility that banks might once again get stuck with debt they’ve committed for acquisitions.Most Read from BloombergHousing Agency Aims to Relocate Its DC HeadquartersLocal Governments Vie for Fired Federal WorkersMetro-North Is Faster Than Acela on NYC-New Haven Route After Signal UpdatesWhat Would ‘Transportation Abundance’ Look Like?Hochul Says Trump’s Tariffs Are Already Hurting New York Eco",https://finnhub.io/api/news?id=dcdf8afa08c74dfb7bc324925a7e4269a01e0ba35515a963fc3095e192cb5781,Yahoo,neutral,0.9151
2025-04-05 08:14:13,"Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout",,https://finnhub.io/api/news?id=5819a095f5ce7ff62af0002f01ef824941e9b6f627ef88cbc30cd37e023de276,SeekingAlpha,positive,0.6097
2025-04-05 08:00:00,"5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (April 2025)","We discuss five discounted, large-cap dividend stocks for stable growth and income. Read here for our filtering process for top DGI picks.",https://finnhub.io/api/news?id=a6d9de19c396701d482892fc3ddcb18bd7765e7a83f5a8f9f7304c93cdc7cd9a,SeekingAlpha,negative,0.8449
2025-04-04 18:35:30,Johnson & Johnson's Tremfya Shows Efficacy In Late-Stage Psoriatic Arthritis Study,Johnson & Johnson (NYSE:JNJ) on Friday announced topline results from Phase 3b APEX study of Tremfya (guselkumab) in patients with active psoriatic arthritis (PsA) who are biologic naïve and have had an inadequate response to standard therapies. The study achieved its primary endpoint (ACR20a) of reducing signs and symptoms and its major secondary endpoint of reducing progression of structural damage as measured by radiographic progression at 24 weeks compared to placebo. In the Phase 3b APEX st,https://finnhub.io/api/news?id=9756afccad576fc1bfcb5910d2497e3a27cd42db0cd2b38571531b7ccb284e42,Yahoo,negative,0.9248
2025-04-04 13:04:00,The Zacks Analyst Blog Highlights Johnson & Johnson and Pfizer,Johnson & Johnson and Pfizer are part of the Zacks top Analyst Blog,https://finnhub.io/api/news?id=ae246bbde822dc8bf43585c2f475d490ec308d940338bb60f74d2d50bd966320,Yahoo,positive,0.935
2025-04-04 13:01:12,"1 Ideal Buy From 23 ""Safer"" April Dividend Dogs In 50 Fortune World's Most Admired Companies (FWMAC)",Discover top investment opportunities: Fortune 50 highlights admired companies with strong dividends. Read the full list of stock picks here on Seeking Alpha.,https://finnhub.io/api/news?id=32d998c2fae31ad28c34ec6e39c3013ff821c16b7608d3c185838636ef8c20c7,SeekingAlpha,positive,0.6212
2025-04-04 12:05:00,TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis,"Johnson & Johnson (NYSE: JNJ) today announced that the TREMFYA® (guselkumab) Phase 3b APEX study achieved both its primary endpoint (ACR20a) of reducing signs and symptoms and its major secondary endpoint of reducing progression of structural damage as measured by radiographic progression at 24 weeks, in adults living with active psoriatic arthritis (PsA), compared to placebo.1",https://finnhub.io/api/news?id=591b464416746009a30079dc6d65477f1ae2b357040db7b5929ed3507e8f3033,Yahoo,negative,0.8795
2025-04-04 11:21:32,Johnson & Johnson Global Survey Reveals Confidence in AI and Medical Technology to Address Personalized Needs of the Aging Population and Alleviate Burnout Among Healthcare Professionals,"New Brunswick, NJ. - With the global population over 60 expected to double by 2050, the healthcare industry faces significant challenges, increasing the need for specialized care for age-related...",https://finnhub.io/api/news?id=4f47268a25763dd137fca74782d4cd529f9d780ea6d94f15f64bd7c088744ed9,Finnhub,negative,0.9402
2025-04-04 07:00:28,Nanobiotix SA (NBTX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges,"Despite a significant net loss, Nanobiotix SA (NBTX) extends its cash runway and strengthens its partnership with Johnson & Johnson.",https://finnhub.io/api/news?id=92305d924239b9e03779e0dd93437d580b8952aa9bf3a8a504af7fe46dba722d,Yahoo,negative,0.9299
2025-04-03 19:39:07,FDA delay on Novavax vaccine approval could be bellwether for vaccine sector: BofAS,"The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has passed with no clarity on when the decision will move forward again.",https://finnhub.io/api/news?id=5b68a6a0d1e4e6384f95ff881555072a0e5c2882dc631d987b355559b8100ded,Yahoo,positive,0.5785
2025-04-03 18:43:00,"Potatoes, discount chains and drugmakers offer havens in stock-market bloodbath","Potatoes, discount chains and drugmakers offer havens in stock-market bloodbath",https://finnhub.io/api/news?id=f57ab0882a5b1d37612cb12eb44e395004096d9025d533fa7641bd6e86d9b6ca,MarketWatch,neutral,0.8124
2025-04-03 17:57:31,​RxSight: Navigating Market Headwinds Amid Intensifying Competition (Downgrade),RxSight faces revenue decline and rising competition in the IOL market. Explore the impacts of economic uncertainties and why a Hold rating is suggested.,https://finnhub.io/api/news?id=82a3d3d456888286cbb20484ca10ef374b428a10201c646b1aa669881f554304,SeekingAlpha,neutral,0.9099
2025-04-03 14:30:22,"Pharma Stocks Aren't in the Clear, Despite Tariff Exemption—Heard on the Street","Big pharmaceutical stocks mostly rose after President Trump’s executive order exempted medicines from new tariffs. Merck, Bristol-Myers Squibb, and Johnson & Johnson were among the top performers in the S&P 500, with the sector also benefiting from its status as a defensive play.",https://finnhub.io/api/news?id=dafc455d6b043cbaeb717724b5933eb6ce4e53e22c177f5a35f7c74bc43607e6,Yahoo,neutral,0.5785
2025-04-03 13:59:00,JNJ vs. PFE: Which Drug Giant is a Better Buy Now?,Both JNJ & PFE expect their sales and profits to improve in 2025.,https://finnhub.io/api/news?id=577f8440ee8c4800f3fbc99d3e2c2f84078fbcc5869748e44935a4ea9da8042e,Yahoo,positive,0.8579
2025-04-03 09:16:25,J&J: putting AI to work for seniors and caregivers,"With the world's population over 60 expected to double by 2050, the healthcare sector needs to step up specialist care for age-related conditions. At the same time, physician burnout remains a major...",https://finnhub.io/api/news?id=1cce23c3fb26cd863c98dbbbb86e2c259f7dfd0b3a1e800bca9ddbfba209d44b,Finnhub,positive,0.8697
2025-04-02 22:15:00,Worried About the Economy? 2 No-Brainer Buys to Shield Your Portfolio.,"The Nasdaq Composite (NASDAQINDEX: ^IXIC) and the S&P 500 (SNPINDEX: ^GSPC) sank, shifting in and out of correction territory in the first quarter of the year for one big reason: investors have been worried about the economy.  President Donald Trump is putting tariffs on imports, and economists predict this could lead to higher inflation and a slowdown in growth.  Healthcare companies, for example, may excel since people need their medicines or procedures regardless of the economic backdrop.",https://finnhub.io/api/news?id=b11b5cfefe54fe5c4fe7c7c8061dd61cde67d7c4e60ff6ec91cbdf35bed0594b,Yahoo,positive,0.8379
2025-04-02 22:03:35,Big Pharma Avoids Worst-Case Tariff Scenario,"Drugmakers breathed a sigh of relief Wednesday after President Trump didn’t announce pharmaceutical tariffs.  Plus, language in the executive order indicated medicines were exempted from the reciprocal tariffs that Trump did announce.  Drugmakers were combing over the executive order to clarify the exemption language in the executive order and to make sure they won’t be hit by any other tariff provisions, such as the 10% “baseline” tariff.",https://finnhub.io/api/news?id=e56792421f40cd13cbd5b94e4465a2bf24427e7b41aded3c7608a2d37bd75b9a,Yahoo,positive,0.5406
2025-04-02 21:45:15,Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider,"The latest trading day saw Johnson & Johnson (JNJ) settling at $155.36, representing a +1.38% change from its previous close.",https://finnhub.io/api/news?id=e29d90b0b839e5cc3a58889106638c4e9bcbac8c1cf9a375130c6727c2e20927,Yahoo,positive,0.9309
2025-04-02 19:59:19,Sector Update: Health Care Stocks Advance in Late Afternoon Trading,"Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index up 0.4% and the He",https://finnhub.io/api/news?id=173b47b7ec6c269ba32a94c52feb5263b6316d13b722a459235f073f25184151,Yahoo,negative,0.5419
2025-04-02 15:35:40,GSK: Under Threat From 'Double Whammy' Of Vaccine Skepticism And Pharma Tariffs,Explore how U.S. tariffs and vaccine skepticism may impact GSK plc's profitability. Click for my update as tariffs are creating turbulence within the Pharma sector.,https://finnhub.io/api/news?id=8b5a6872f622707437bfacf7a3abc3b4bc02308d2cfdcb04e542ed4d09e9bd4b,SeekingAlpha,neutral,0.9602
2025-04-02 13:50:00,"Dow's 115-point rally led by gains for Goldman Sachs, Amazon.com Inc. stocks","Dow's 115-point rally led by gains for Goldman Sachs, Amazon.com Inc. stocks",https://finnhub.io/api/news?id=21803cd693484d4c9f4cf02fd33326152e0f47b43694659cabd9512b0a318f89,MarketWatch,negative,0.8957
2025-04-02 13:44:25,What's next for Johnson and Johnson after third failed attempt to settle talc laws,"Investing.com -- U.S. Bankruptcy Court Judge Christopher Lopez in the Southern District of Texas rejected a request from Johnson & Johnson's (NYSE:JNJ) subsidiary, Red River Talc, to approve its prepackaged bankruptcy plan.",https://finnhub.io/api/news?id=d6c8ce10d822bcd01fb7feac847ba705afea688ae6ef717237b74695d1a69fc1,Yahoo,positive,0.8754
2025-04-02 13:00:08,Why Investors Need to Take Advantage of These 2 Medical Stocks Now,Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.,https://finnhub.io/api/news?id=fbf07e20289e4278acd6778a8f898025df03a81d8f16fee26f4d06095dd53573,Yahoo,positive,0.9202
2025-04-02 12:56:06,Morning Movers: Johnson & Johnson slips after rejection of Talc case settlement,"Stock index futures are experiencing early declines amid investor apprehension surrounding President Donald Trump’s impending “Liberation Day” tariffs, set to be introduced tomorrow. In the commodities market, gold prices have surged to new record highs as investors seek safe-haven assets amid escalating trade tensions. Spot gold briefly surpassed $3,170 per ounce, highlighting the prevailing market anxiety. ​Meanwhile, oil prices have exhibited modest gains. Investors are closely monitoring dev",https://finnhub.io/api/news?id=0fe6e6b4bc20a25c9ba568b91b4716fbecb7ed324947527ea56c5bd84e9b3e10,Yahoo,neutral,0.9653
2025-04-02 12:44:00,"Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership","NEW BRUNSWICK, N.J., April 02, 2025--Johnson & Johnson (NYSE: JNJ) today announced it has completed its acquisition of Intra-Cellular Therapies, Inc. Intra-Cellular Therapies is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson Innovative Medicine.",https://finnhub.io/api/news?id=e990279925aac6c7adc63c98e031af112f42befe3d1569ac48ded58d8dd414bc,Yahoo,negative,0.5659
2025-04-02 11:21:00,"Goldman Sachs, Johnson & Johnson share gains contribute to Dow's nearly 125-point jump","Goldman Sachs, Johnson & Johnson share gains contribute to Dow's nearly 125-point jump",https://finnhub.io/api/news?id=669f9caacf9d054d907d1d8aa97d244be4c920fcbec0058fae145b9cfb54c0fe,MarketWatch,negative,0.925
2025-04-02 10:35:33,Johnson & Johnson Expects Lower Earnings Impact From Intra-Cellular Therapies Acquisition,Johnson & Johnson (JNJ) expects its pending acquisition of Intra-Cellular Therapies (ITCI) to have a,https://finnhub.io/api/news?id=ff46b1aab5eab09f15c1f68ee546344aeee25fd428c82429ae4531343b87eee8,Yahoo,neutral,0.7906
2025-04-02 09:41:14,"Trending tickers: Tesla, Johnson & Johnson, CoreWeave, Newsmax and Raspberry Pi",The latest investor updates on stocks that are trending on Wednesday.,https://finnhub.io/api/news?id=7df74f9acfb8cb98459bcb013fcedf07bd1896e6e30e1921f04c41a816108a36,Yahoo,positive,0.9469
2025-04-02 08:19:00,"Stock Market News For Apr 2, 2025",Wall Street closed mixed on Tuesday to finish the first trading day of second-quarter 2025 after a choppy session.,https://finnhub.io/api/news?id=93924807f172dccc1bec5b089b3d919fbc2115ab00cf03f1cd676763f4a72099,Yahoo,positive,0.922
2025-04-02 07:30:00,3 Wide-Moat Dividend Stars For A Championship Portfolio,,https://finnhub.io/api/news?id=f0031775d786a034c935b78b14c00a1196b03f5d3fff00e4483f4e703d9525ea,SeekingAlpha,positive,0.7018
2025-04-02 02:45:41,Watch These Johnson & Johnson Levels as Stock Plunges After Judge Rejects Talc Settlement,Johnson & Johnson shares tumbled Tuesday to lead S&P 500 decliners after the health care giant failed to reach a settlement in liability cases related to its baby powder and other talc products. Monitor these key chart levels.,https://finnhub.io/api/news?id=47043a379ca2efec2f1a18c86572c59fc8100e4510e2c7cbd21da8b38e899ada,Yahoo,neutral,0.9191
2025-04-02 00:10:00,Lord Abbett Affiliated Fund Q4 2024 Commentary,"The Fund returned 0.07% reflecting performance at the net asset value of Class I shares with all distributions reinvested for the quarter ended September 30, 2024.",https://finnhub.io/api/news?id=34fcbc832900af9ec3ffc7cc0967bc2183304e0d3b2ae4b0d7f90f6adcdb2610,SeekingAlpha,positive,0.9216
2025-04-01 21:06:02,S&P 500 Gains & Losses Today: Johnson & Johnson Drops as Judge Rejects Liability Settlement,"The S&P 500 edged 0.4% higher on Tuesday, April 1, ahead of Wednesday's anticipated rollout of reciprocal tariffs by Donald Trump's administration.",https://finnhub.io/api/news?id=df4f122f105911d371f75008b8dd229ebd0f04fa1d11f30d2c4ce5bfff0a0565,Yahoo,neutral,0.9607
2025-04-01 20:48:47,"Hims & Hers adds Eli Lilly GLP-1 drugs, Johnson & Johnson setback","Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination to discuss some of the top stories of the trading day, including Johnson & Johnson's (JNJ) setback in its litigation. Additionally, Hims & Hers (HIMS) expanded its offerings, adding Eli Lilly's (LLY) GLP-1 drugs to its telehealth platform, following its earlier partnership with Novo Nordisk. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",https://finnhub.io/api/news?id=16c699b332de57394a58b8070aba6ae3a3bec745ff109be2aa73ba7125a2e757,Yahoo,positive,0.788
2025-04-01 20:06:00,Johnson & Johnson Announces Expected Closing Date for Intra-Cellular Acquisition,"NEW BRUNSWICK, N.J., April 01, 2025--Johnson & Johnson (NYSE: JNJ) today announced that following the approval of its pending acquisition of Intra-Cellular Therapies, Inc. by Intra-Cellular Therapies’ shareholders on March 27, 2025, Johnson & Johnson intends to complete its acquisition of Intra-Cellular Therapies on or around April 2, 2025.",https://finnhub.io/api/news?id=2f216126ca22988d0a8ef10c48bdbb75b6eba9dea21c4e2b29a68c23391d4d1c,Yahoo,positive,0.9231
2025-04-01 19:50:15,Equity Markets Mixed Amid Weak Manufacturing Data,"US benchmark equity indexes are on track to close mixed on Tuesday, as March US manufacturing data s",https://finnhub.io/api/news?id=6bb359bf6c20a58a2f461aa914fc735aed484a9e2137883ae93f181fd9e2f33d,Yahoo,neutral,0.96
2025-04-01 19:33:15,"Stocks to Watch Recap: J&J, Xiaomi, PVH, XPeng",↗️ Newsmax (NMAX): The media company's shares rose sharply for a second straight day after a wild stock-market debut. The stock rose 179% on the day to close at $233. ↘️ Johnson & Johnson (JNJ): A judge dismissed J&J's third attempt to resolve its mass talcum powder liabilities through chapter 11 bankruptcy.,https://finnhub.io/api/news?id=ac986e31a245f3fb4e9340ad1df315a2c1df17cc897702c453ab8dd611620543,Yahoo,positive,0.9354
2025-04-01 18:38:12,Why Johnson & Johnson Stock Is Sinking Today,"Shares of Johnson & Johnson (NYSE: JNJ) are tumbling on Tuesday.  The drop comes as the S&P 500 and Nasdaq Composite were down 0.4% and 0.1%, respectively.  A bankruptcy judge in Texas dismissed J&J's latest attempt to settle thousands of lawsuits that allege its baby powder and other talc-based products caused ovarian cancer.",https://finnhub.io/api/news?id=d13e60485572ef5ddbe50a10287c2b4a1b96a97cb07ff639bd674bb8cb88e5e3,Yahoo,neutral,0.8673
2025-04-01 18:03:49,Sector Update: Health Care Stocks Fall Tuesday Afternoon,Health care stocks fell Tuesday afternoon with the NYSE Health Care Index dropping 1.4% and the Heal,https://finnhub.io/api/news?id=f1eb9dde75653d6da26fc2bc425cd91f6bba42b1aaf95fa56ab1f0262dbd7a8c,Yahoo,neutral,0.9732
2025-04-01 17:19:00,Health Care Down as J&J Slides -- Health Care Roundup,Health Care Down as J&J Slides -- Health Care Roundup,https://finnhub.io/api/news?id=8246471ca1d5db09e945a05bcbe196d7311b6c33d0377465a7fabb5992e32771,MarketWatch,neutral,0.8973
2025-04-01 17:12:10,Johnson & Johnson's Third Attempt at Talc Bankruptcy Plan Rejected,"A Texas judge rejected J&J's third attempt to use bankruptcy to settle talc lawsuits, forcing litigation.",https://finnhub.io/api/news?id=9403ac990964928f4f2a3d9bd808d9f7c012d27b1d263c581af0dc4ba156265b,Yahoo,positive,0.8525
2025-04-01 17:05:30,"FDA clears Bolt Medical’s IVL system, backing Boston Scientific’s $664m buyout",The intravascular lithotripsy market has undergone high growth trailblazed by J&J subsidiary Shockwave Medical.,https://finnhub.io/api/news?id=97882ec59f886dd92856d986867aa4d9f9bd733ce831c4e4bc3eae6459a9bd38,Yahoo,negative,0.9009
2025-04-01 16:47:03,J&J Stock Slumps as Company Fails to Settle Talc Cases,"Johnson & Johnson shares fell Tuesday, after the company said a judge rejected its proposed plan to settle thousands of claims alleging its baby powder and other talc products cause ovarian cancer.",https://finnhub.io/api/news?id=2084fb6d0579c3e6efb5d39761b4d27e283cc750a78cc781ab02a90c46f87cfc,Yahoo,neutral,0.962
2025-04-01 16:45:37,Johnson & Johnson Stock Falls After Judge Rejects Bankruptcy Strategy,"Federal Judge Blocks J&J Bankruptcy Plan, Shares Slide",https://finnhub.io/api/news?id=c48a034ddf5760aebe4cb492cc7c247e95671d1d64a34d264075cf6f78daf136,Yahoo,neutral,0.9528
2025-04-01 16:25:19,Why Johnson & Johnson (JNJ) Shares Are Falling Today,Shares of multinational healthcare company Johnson & Johnson (NYSE:JNJ) fell 5.6% in the morning session after a judge in Texas rejected the company's third attempt to use bankruptcy as a legal shield against lawsuits alleging its talcum powder products caused ovarian cancer.,https://finnhub.io/api/news?id=34504a7afec65424ab89e1986ddfd5c726e13eb32aef3a5ee621bd1eed8f1b76,Yahoo,neutral,0.9648
2025-04-01 16:10:11,Can Johnson & Johnson (JNJ) Keep the Earnings Surprise Streak Alive?,Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,https://finnhub.io/api/news?id=9ba4163f080ba448849efabc5ad9618b39fdafb7ded7064ff5dcc056697ab571,Yahoo,positive,0.6608
2025-04-01 16:01:19,J&J Dives After Judge Tosses Out $10 Billion Talc-Based Bankruptcy Plan,J&J Dives After Judge Tosses Out $10 Billion Talc-Based Bankruptcy Plan,https://finnhub.io/api/news?id=e4a9abf3d5880d82c3ca2db2881a83c9d5ce9c506c0eac2735d2a3fa866fe4c8,DowJones,neutral,0.9532
2025-04-01 15:53:41,Judge rejects J&J’s $9bn talc settlement for third time,J&J will now reallocate $7bn of funds previously set aside for the bankruptcy resolution.,https://finnhub.io/api/news?id=11d1fa12ac06e4211e8310638266416f50bd19898bdb46fa8cd7c4fb17560442,Yahoo,neutral,0.9191
2025-04-01 15:44:37,"Reshoring efforts in US FMCG business begins, but cost increases are likely",J&J's example is likely to be replicated across FMCG industries as US businesses seek to balance their globalised supply chains with a domestic US capability.,https://finnhub.io/api/news?id=f1bf4d9a19976192093663b220257031ee9c255a46d0dcdee6e42736cda7ef4f,Yahoo,negative,0.9507
2025-04-01 15:38:47,Top Midday Stories: Ford US Sales Fall 1.3% Year Over Year in Q1; Judge Denies Johnson & Johnson Unit's Bankruptcy Plan,"The Dow Jones Industrial Average and S&P 500 Index were down in late-morning trading Tuesday, while",https://finnhub.io/api/news?id=23be9af856ca0c3f60581c5a19e98260974caec8d29fc84da1e8b6af6992d23d,Yahoo,neutral,0.9724
2025-04-01 15:30:00,"Dow falls nearly 150 points on losses for Johnson & Johnson, Merck shares","Dow falls nearly 150 points on losses for Johnson & Johnson, Merck shares",https://finnhub.io/api/news?id=c9d70736961831c69fccafebef0832d2e0f9e5e864e8e345b889072023cf7e19,MarketWatch,neutral,0.9574
2025-04-01 15:19:12,"Lucid, Johnson & Johnson, PVH: Market Minute","Madison Mills outlines the top stories of the day as part of Tuesday morning's Market Minute, including Lucid Group (LCID) gaining market share from Tesla (TSLA), Johnson & Johnson's (JNJ) bankruptcy case, and PVH's (PVH) stronger-than-expected outlook. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",https://finnhub.io/api/news?id=71718d94f462f6bf93325c649212ae3ccb8ac60b7a9318660cefa9b38836a33f,Yahoo,positive,0.9337
2025-04-01 15:09:56,Judge rejects Johnson & Johnson's talc settlement,J&J's attempt to finally settle the ongoing talc lawsuits hit a new speed bump Tuesday when a bankruptcy judge denied the company's attempt to resolve the litigation.,https://finnhub.io/api/news?id=bfa5c46334d70d950424f1042b1b5805a3c0978098454c2343446991d7caee09,Yahoo,neutral,0.8637
2025-04-01 14:29:00,"Dow's nearly 275-point fall led by losses for shares of Johnson & Johnson, Merck","Dow's nearly 275-point fall led by losses for shares of Johnson & Johnson, Merck",https://finnhub.io/api/news?id=8e6e1a2f58a2d0a1a80bde14e20a8bd4d965f6e8d850f32e0eea68e022b932d7,MarketWatch,neutral,0.9686
2025-04-01 14:27:17,Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns,"Takeda boosts profit margins with AI-driven growth, FY2024 guidance upgrade, share buyback plan & promising drug launches.",https://finnhub.io/api/news?id=dbb176953bcfea3c836392e3714215f704cd8387fe1385bb52bdfcf24b56350c,SeekingAlpha,negative,0.9516
2025-04-01 14:07:28,Update: Johnson & Johnson Faces Setback as Bankruptcy Court Denies Talc Settlement Plan,(Updates with the recent stock move in the first paragraph.) Johnson & Johnson (JNJ) shares were,https://finnhub.io/api/news?id=07143e06b6b5bc2d09039852daabf6aeff2786aaf5b5a6b00ffd32f61bdefebe,Yahoo,neutral,0.9662
2025-04-01 14:01:19,"Tesla, PVH, Johnson & Johnson: Trending Tickers","Madison Mills and Julie Hyman, joined by Yahoo Finance Senior Reporter Anjalee Khemlani, outline what's driving interest in some of the top trending tickers on Yahoo Finance's platform. Tesla (TSLA) sales in France saw a 37% year-over-year drop as the electric vehicle (EV) pioneer faces headwinds fueled by CEO Elon Musk's involvement in US President Donald Trump's second administration. Conversely, Ford (F) saw US retail sales rise 19% in March, just ahead of Trump's auto tariffs taking effect. PVH (PVH), the parent company of Calvin Klein and Tommy Hilfiger, gained after issuing a positive outlook. Johnson & Johnson (JNJ) stock fell after a judge denied the company's attempt to resolve a talc lawsuit through bankruptcy. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",https://finnhub.io/api/news?id=e4904336bcb43ff30ed6f9ea92268be8f6bb605b61b98e0804b6fa4f0c6b1dd4,Yahoo,positive,0.9255
2025-04-01 13:58:00,Johnson & Johnson Stock Falls After Talc Resolution Rejected by Judge. The Problem Won’t Go Away Soon.,A bankruptcy judge in Texas rejected a proposal that would have ended most lawsuits saying the products cause ovarian cancer.,https://finnhub.io/api/news?id=f891611346de6d055bd7710a8268c5a06bbaef9ded93762515613df9d9b29c40,Yahoo,neutral,0.9605
2025-04-01 13:57:04,Johnson & Johnson (JNJ): Among the Best Healthcare Stocks to Buy According to Billionaires,"We recently published a list of 10 Best Healthcare Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best healthcare stocks to invest in. Healthcare stocks experienced a challenging year in 2024, lagging behind high-growth sectors like tech and […]",https://finnhub.io/api/news?id=6f5ed4ab9438d027ab0183e6344272bb946b35aae83578e693052458f25c255e,Yahoo,negative,0.7916
2025-04-01 13:33:48,"Stocks to Watch Tuesday: J&J, Xiaomi, PVH, XPeng",↘️ Johnson & Johnson (JNJ): A judge dismissed J&J's third attempt to resolve its mass talcum powder liabilities through chapter 11 bankruptcy. Shares fell 5% in midday U.S. trading. ↗️ XPeng (XPEV): The Chinese Tesla rival posted a jump in monthly and quarterly sales.,https://finnhub.io/api/news?id=a2aed2aecfb6bd8348854029aece71a73ff1103d5d2c066c88ba9d7d164f135a,Yahoo,positive,0.9272
2025-04-01 13:30:00,J&J's Third Bankruptcy Attempt to End Talc Suits Rejected,J&J fails in its third attempt to settle tens of thousands of lawsuits claiming its talc-based powder caused cancer.,https://finnhub.io/api/news?id=9b059caedc60051847542a70881dd19497a84e1348a4ee6f44e9540d48c7323c,Yahoo,neutral,0.7099
2025-04-01 13:28:00,"Dow drops 100 points on losses in shares of Johnson & Johnson, Merck","Dow drops 100 points on losses in shares of Johnson & Johnson, Merck",https://finnhub.io/api/news?id=eb1dd4ba392c83d929f251858695639e83e0182ceadac3113a5a949f2ca960b8,MarketWatch,neutral,0.9504
2025-04-01 12:26:27,Bankruptcy judge denies J&J settlement plan related to baby powder containing talc,"A U.S. bankruptcy court judge has denied Johnson & Johnson's settlement plan related to baby powder containing talc, providing another setback in the company's efforts to resolve the matter.  This is the third bankruptcy case for a J&J company as it relates to the baby powder issue.  Red River Talc LLC, a J&J subsidiary, was seeking confirmation of a proposed prepackaged Chapter 11 bankruptcy plan that would have been one of the biggest mass tort settlements in history, if approved.",https://finnhub.io/api/news?id=34c7213e6fa3c7057aeda8078d5b3284df38026f0ed1ce455a0f596bc51da03f,Yahoo,neutral,0.8812
2025-04-01 12:05:47,Dogs Of The Dow Chase April's 'Safer' Buy,,https://finnhub.io/api/news?id=2feed9044f044f2d4cb8422e3537e5db1ce869843f4c4367a375d4fa0a997d66,SeekingAlpha,negative,0.7423
2025-04-01 11:44:21,"Nvidia, Other Techs Hurt Dow Jones, But These Names Outperformed In Q1","The overseers of the Dow Jones Industrial Average might regret adding Nvidia to the index.  Since it joined the Dow industrials on Nov. 7, Nvidia stock is down nearly 30%.  Nvidia stock is on track for its worst month since September 2022, when it lost nearly 20%, according to Dow Jones Market Data.",https://finnhub.io/api/news?id=97e400b522bf5e518c45d955870c9c3706affed7b7ff749600e31a67ec75a38d,Yahoo,neutral,0.9196
2025-04-01 11:33:20,J&J stock drops after failed attempt to end talc claims,"Investing.com -- A U.S. bankruptcy judge has dismissed Johnson & Johnson’s third attempt to resolve its widespread talc-related lawsuits through Chapter 11, marking another setback in the company’s efforts to end the litigation.",https://finnhub.io/api/news?id=6290c955fec8e4b0ee146595effbaf62b19f498ddf3f91cd88db203055c82010,Yahoo,neutral,0.9419
2025-04-01 11:28:15,Johnson & Johnson named to Fortune's 2025 America's Most Innovative Companies list,Innovation is a concept that is at the heart of everything Johnson & Johnson does and it's a core part of Our Credo-the mission statement that has guided the company for more than 80 years.Once...,https://finnhub.io/api/news?id=a630f10cbf3b24a056269750fa780843bfb7364a5c923bf8175516750788f0bd,Finnhub,negative,0.6128
2025-04-01 11:27:16,"Trending tickers: Tesla, Moderna, Newsmax, Johnson & Johnson and Travis Perkins",The latest investor updates on stocks that are trending on Tuesday.,https://finnhub.io/api/news?id=37c7aacd6edd990b639e66860f7b4b24fc51b6b6fb7f791287597fcb15bed199,Yahoo,positive,0.9479
2025-04-01 11:11:05,J&J shares tumble as judge rejects $10 billion talc settlement,"It faces lawsuits from more than 60,000 claimants alleging its baby powder and other talc products contained asbestos and caused ovarian cancer.  J&J plans to ""return to the tort system to litigate and defeat these meritless talc claims"", and does not plan to appeal the ruling.",https://finnhub.io/api/news?id=bd5b3e24cdb7d0637be291d21892b333bd5bf2399f91fb532f436b0f173ad6f4,Yahoo,neutral,0.9439
2025-04-01 10:51:00,"Dow's 150-point fall led by losses for Johnson & Johnson, Merck shares","Dow's 150-point fall led by losses for Johnson & Johnson, Merck shares",https://finnhub.io/api/news?id=7e04b62a34c728a42fbd843129a5ecde9a713dd142a87bbafd1a316103631111,MarketWatch,neutral,0.9632
2025-04-01 09:51:07,J&J to fight talc lawsuit in court as Red River bankruptcy plan denied,,https://finnhub.io/api/news?id=10c0978bc2c5e35c9d0bdd8b7bcb9c276b8559304eabf2abcb7b861839ad8e03,Fintel,positive,0.4374
2025-04-01 09:45:00,"Dow's 275-point drop led by losses for Johnson & Johnson, Boeing shares","Dow's 275-point drop led by losses for Johnson & Johnson, Boeing shares",https://finnhub.io/api/news?id=f722a776f2dc3f4e8e8704c3e65a2aaed943aac002f3c401614299af56e38521,MarketWatch,neutral,0.9683
2025-04-01 09:40:19,J&J: stock down after an unfavorable court ruling,"Johnson & Johnson is down over 4%, the day after the US Bankruptcy Court for the Southern District of Texas rejected its proposal to settle litigation involving its Red River Talc subsidiary as part...",https://finnhub.io/api/news?id=23679a0da01b680e6663ccb3e1d1144646fc46514c44cca3432afe83f936e091,Finnhub,neutral,0.9686
2025-04-01 09:30:04,"Federal Judge Rejects Johnson & Johnson Bankruptcy Strategy, Paving Way for Talc Victims to Seek Justice in Trial Courts",Court ruling marks major victory for ovarian cancer patients as legal battle shifts to multidistrict litigation...,https://finnhub.io/api/news?id=6612a5e33a45a92e6e2d53aabf4753d08cf7e3a2afd9d9b582ef37fb1ed974dc,Finnhub,neutral,0.8136
2025-04-01 09:10:52,J&J shares fall after judge rejects $10 billion talc settlement,Shares of Johnson & Johnson fell more than 4% on Tuesday after a U.S. bankruptcy judge rejected its $10 billion proposal to end tens of thousands of lawsuits alleging that its baby powder and other...,https://finnhub.io/api/news?id=71afb34ad078b2c29067a94c0ec20127827a8dbff57ecdbf19b896e01f3d220c,Finnhub,neutral,0.9476
2025-04-01 09:02:00,"These Stocks Are Moving the Most Today: Tesla, XPeng, J&J, PVH, Newsmax, Southwest, and More","These Stocks Are Moving the Most Today: Tesla, XPeng, J&J, PVH, Newsmax, Southwest, and More",https://finnhub.io/api/news?id=0f24aa8598132b91dd7b82c35994adb6b31d0283fbe6d40e341846c7d88d3a3b,MarketWatch,positive,0.8323
2025-04-01 09:01:46,U.S. judge blocks third attempt by Johnson & Johnson to settle talc issue via bankruptcy,Copyright © BusinessAMBE 2023Key takeawaysA federal judge has rejected Johnson & Johnson's third attempt to settle talc claims through bankruptcy proceedings.The judge found that the voting...,https://finnhub.io/api/news?id=12188403fa391d179944683bbb903ce716e3c7a2d615c52142bc459ad91a05c4,Finnhub,neutral,0.7593
2025-04-01 08:15:00,Johnson & Johnson Stock Falls After Latest Talc Resolution Rejected by Judge,Johnson & Johnson Stock Falls After Latest Talc Resolution Rejected by Judge,https://finnhub.io/api/news?id=564ccd4674f2f1c5cedcd96dd31716008d796c8946a5f7e047bc7a8b8affbcb0,MarketWatch,neutral,0.9371
2025-04-01 03:02:00,Johnson & Johnson’s Third Bankruptcy Case for Talc Lawsuits Thrown Out,Bankruptcy judge rejects the healthcare-products company’s third attempt to resolve mass talc lawsuits through chapter 11.,https://finnhub.io/api/news?id=35013039214df297608964d7137db949060feefa5ee048269b007288d5f752f5,Yahoo,neutral,0.8611
2025-04-01 02:20:00,Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims,"NEW BRUNSWICK, N.J., April 01, 2025--Today, the U.S. Bankruptcy Court for the Southern District of Texas denied the request by Johnson & Johnson (NYSE: JNJ) (the ""Company"") subsidiary Red River Talc LLC (""Red River"") to confirm its proposed prepackaged bankruptcy plan—notwithstanding that it offered one of the largest settlements ever proposed in a mass tort bankruptcy and was supported by the overwhelming majority of claimants.",https://finnhub.io/api/news?id=7e5cdd1626fa0f4ecb3d2c84451f580f0da805cff163d858bcfbc420acfc6778,Yahoo,negative,0.8344
2025-03-31 16:07:23,Best Dividend Aristocrats For April 2025,"Dividend Aristocrats in 2025 show resilience, outperforming the S&P 500. Click here to read what investors need to know.",https://finnhub.io/api/news?id=8d2f7e6be3053b554cc8ee87405abf96ff95f26b38f72e7f7cdf82cef0d639bd,SeekingAlpha,positive,0.8936
2025-03-31 15:45:08,Are You Looking for a High-Growth Dividend Stock?,"Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.",https://finnhub.io/api/news?id=98403681fdba12520898e7dc2dcc91989bc9a8672e720e4b83c8e3f60013e5e9,Yahoo,positive,0.9056
2025-03-31 13:36:35,Johnson & Johnson (JNJ): Among the Best Dividend Aristocrat Stocks with Over 3% Yield,"We recently published a list of the 15 Best Dividend Aristocrat Stocks with Over 3% Yield. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best dividend aristocrats with a high yield. Dividend Aristocrats are the companies that have raised their payouts for 25 consecutive […]",https://finnhub.io/api/news?id=ff66259de9445c9854f6ab35b7f37f54840b209fdeac5ca1e0c8e497056b6424,Yahoo,negative,0.9035
2025-03-31 13:30:00,RDY & Bio-Thera Ink Deal for JNJ's Stelara/Simponi Biosimilar,Dr. Reddy's inks collaboration deal with Bio-Thera to develop and commercialize proposed biosimilar candidates of J&J's Stelara and Simponi in Southeast Asia.,https://finnhub.io/api/news?id=2773ab609e61ad22906a0206ba8fbb465ae5eb55308723b21508b88063cb85c5,Yahoo,positive,0.7695
2025-03-31 13:01:53,1 Healthcare Stock to Target This Week and 2 to Turn Down,"Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 11.1%. This drop was worse than the S&P 500’s 4% decline.",https://finnhub.io/api/news?id=70cf00c471c5a3487d6fe002761b6cc0869dd2cd1109a7ecd7768740deb86de0,Yahoo,positive,0.6887
2025-03-30 17:52:13,"Procter & Gamble, Johnson & Johnson Among 10 Companies To Announce Dividend Increases In First Half Of April",Discover predictions for upcoming dividend increases from top companies with long-term growth. Learn which stocks to watch this April.,https://finnhub.io/api/news?id=5503695869030fb0a8e79bf30a7a19ee6be98c31dc0ee9344d42df26b3dffc3b,SeekingAlpha,negative,0.8304
2025-03-30 05:00:00,Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors,Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain for investors.,https://finnhub.io/api/news?id=e065d0a1e1188ee694cc2bc6539fc5b42f511784f8985ea5256abcfe2f272f87,SeekingAlpha,positive,0.7355
2025-03-29 13:54:41,Jim Cramer on Johnson & Johnson (NYSE:JNJ): Their Spinoff Was Ill-Advised,"We recently published a list of Jim Cramer Says Trump’s Tariff Strategy Is Working & Discusses These 11 Stocks. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discussed. In a recent appearance on CNBC’s Squawk on the Street, Jim Cramer […]",https://finnhub.io/api/news?id=1e11e09f12f40c631daf42e22e27828d787719019aea571909e7ce4921732ad5,Yahoo,neutral,0.8723
2025-03-29 10:45:00,3 Relatively Safe Stocks to Buy Right Now,"Investing in stocks comes with risks.  David Jagielski (Abbott Laboratories): If you're looking for safety within the healthcare sector, a top name to consider right now is Abbott Laboratories.  For starters, it offers an above-average dividend yield of 1.9% (the S&P 500 average is 1.4%).",https://finnhub.io/api/news?id=0696f08fa85a087be9e7445ffb72a8a52c86bd803ed14dff46351ac52d134873,Yahoo,positive,0.8661
2025-03-29 07:00:00,If I Could Only Choose 5 Dividend Stocks For My Retirement Portfolio,Focus on companies with strong balance sheets and sustainable dividends for retirement. See why these five stocks offer great risk-reward and growth potential.,https://finnhub.io/api/news?id=145e0f7fb23806abc83c98b9296e28c7bfc7eda2a36c9f8088da2a6eb2b96952,SeekingAlpha,positive,0.9502
2025-03-28 19:55:33,Sector Update: Health Care Stocks Softer Late Afternoon,"Health care stocks eased late Friday afternoon, with the NYSE Health Care Index down 0.1% and the He",https://finnhub.io/api/news?id=5f49b028de650a1dfcf36d9f9a966156bcc377d12e1e8a3761f7c168537bee37,Yahoo,neutral,0.8598
2025-03-28 16:40:23,Johnson & Johnson Needs Time To Consolidate (Technical Analysis And Downgrade),Johnson & Johnson's long-term prospects are promising due to strong drug pipeline developments and significant R&D investments. Read what could be next for shares in this healthcare giant.,https://finnhub.io/api/news?id=7ba4c42e0d4508191cc139b945ea1be843422151fc91c492cfc1eb48c86e71af,SeekingAlpha,positive,0.7553
2025-03-28 16:18:39,Johnson & Johnson unit ordered to pay $1.64 billion in HIV drug marketing case,"A federal judge ordered a Johnson & Johnson unit on Friday to pay the U.S. government $1.64 billion after a jury found it liable in a whistleblower lawsuit for illegally promoting the HIV drugs Prezista and Intelence.  U.S. District Judge Zahid Quraishi in Trenton, New Jersey, ordered the drugmaker's Janssen unit to pay $360 million for violating the federal False Claims Act.  He also imposed $1.28 billion in civil fines, or $8,000 for each of 159,574 false claims the jury found were submitted to programs such as Medicare, Medicaid and the AIDS Drug Assistance Program.",https://finnhub.io/api/news?id=6c30fa2046de27bc9bef6c24700301d957d14423255e86be97739552a2225301,Yahoo,neutral,0.9608
2025-03-28 14:41:00,J&J launches energy generator compatible with Ottava robot,Johnson & Johnson said the Dualto energy system’s design allows for up to 46% less footprint than separate generators.,https://finnhub.io/api/news?id=940e05ddbe2132d460fd643f5dd989759cb08384e1450f45ad009fe6552b0298,Yahoo,negative,0.6312
2025-03-28 09:41:30,Johnson & Johnson MedTech to Highlight Latest Advancements in Heart Disease Treatment with Impella at ACC.25,"Danvers - Johnson & Johnson MedTech, the global leader in heart recovery, will feature the latest evidence demonstrating the survival benefit of Impella heart pump technology at the American College...",https://finnhub.io/api/news?id=9f441e27ecd16b80d8d3ce4ef830055df7f9045a481ffd2a79d2d0fd68fe8382,Finnhub,positive,0.5501
2025-03-28 09:11:57,2 Reasons to Like JNJ and 1 to Stay Skeptical,"Since September 2024, Johnson & Johnson has been in a holding pattern, posting a small return of 0.7% while floating around $163.19.",https://finnhub.io/api/news?id=a1db944ed09fb42f65373dc37ed324cb2b299cc262456d49a399c2b0670b23bd,Yahoo,positive,0.8847
2025-03-27 20:47:50,Tracking Cliff Asness' AQR Capital Management 13F Portfolio - Q4 2024 Update,"AQR Capital Management's portfolio grew to $77.63B with top stakes in Apple, Nvidia, Microsoft, Amazon and Alphabet. Read here for a portfolio update.",https://finnhub.io/api/news?id=0f9f76ea1dfc19d71fbc8d6eed19477e768ee0f4440a5d4f249cf95c4ca85f2c,SeekingAlpha,positive,0.9392
2025-03-27 17:21:06,Johnson & Johnson (NYSE:JNJ) Presents Promising Nipocalimab Data At AAN Annual Meeting,"Johnson & Johnson (NYSE:JNJ) experienced an 11% price increase over the last quarter. This movement coincided with several corporate developments, including the presentation of breakthrough research on nipocalimab at the American Academy of Neurology meeting, and the announcement of FDA fast track designations for its treatments. Additionally, the potential acquisition talks of Intra-Cellular Therapies and strong sales figures in Q4 2024 were pivotal in maintaining investor interest. Launches...",https://finnhub.io/api/news?id=b8dcea1b9f069558ff41d6253cc6135d4e44c95e4bf5cf2cd8cb4a6098abfe30,Yahoo,negative,0.9418
2025-03-27 15:50:09,J&J says Rybrevant/Lazcluze outperforms osimertinib OS in Phase 3 study,Johnson & Johnson announced results for the “gold standard endpoint in cancer treatment” of overall survival from the Phase 3 MARIPOSA study. Head-to-head comparison data versus osimertinib showed Rybrevant plus Lazcluze significantly extended OS in the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or L858R substitution mutations. Median OS is projected to exceed one year beyond the median o,https://finnhub.io/api/news?id=e43793605daa66e2ead114f1a5c374e029595bb1c1e82ee87c22aff57a155397,Yahoo,negative,0.9527
2025-03-27 14:13:04,How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain,"Tariff uncertainty has cast a pall over medical stocks. Re-shoring is possible, but expensive, leaving them in a ""wait-and-see"" pattern.",https://finnhub.io/api/news?id=6ddb50eb5b3605adb9a4f9ae65a9a63fbfee3e28e700e07ecba34a73a219e00b,Yahoo,positive,0.5075
2025-03-27 13:00:16,Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know,"Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.",https://finnhub.io/api/news?id=622ab5d7157bd30cd6c271e38d87e54f3890e11bdef99985d7de7e9db86aec0b,Yahoo,positive,0.9438
2025-03-27 12:19:57,J&J’s NSCLC combo projected to extend survival by one year over Tagrisso,The Rybrevant and Lazcluze combination reduced the risk of death by 25% compared to AstraZeneca’s Tagrisso.,https://finnhub.io/api/news?id=eda336580f3a4f707c3c5c15d6ce3edfb8a1f94bdef6c205718751305c07332c,Yahoo,negative,0.9225
2025-03-27 09:25:00,2 Recession-Proof Dividend Stocks to Buy and Hold,Medtronic (NYSE: MDT) and Johnson & Johnson (NYSE: JNJ) are excellent examples along those lines.  Medtronic and Johnson & Johnson provide some of these products and services.  Medtronic is one of the largest medical device companies in the world.,https://finnhub.io/api/news?id=48a8b90dc8e51001b8758d678e78957940831921ceafd37a9be288a32cf221ee,Yahoo,positive,0.8917
2025-03-27 02:10:07,Plaintiffs Double Down On Challenges To PBM Arrangements In Class Action Lawsuits Involving Johnson & Johnson And JPMorganChase,"On March 10, 2024, the plaintiffs filed an amended complaint in a much-followed putative class action lawsuit against Johnson & Johnson alleging that the plan fiduciaries for J&J's group health plan...",https://finnhub.io/api/news?id=39258b36aff3a234bee2e0a9c579aa441f7e8dedee98a1d082d0ff01a22bccf6,Finnhub,neutral,0.9493
2025-03-26 19:40:11,Jim Cramer Highlights Johnson & Johnson (JNJ) as a Rare Winner Amid Market Sell-Off,"We recently published a list of Jim Cramer Focused On These 9 Stocks Recently. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discussed recently. Jim Cramer, host of Mad Money, expressed his frustration on March 19 about how investors often […]",https://finnhub.io/api/news?id=d1b87fd9d1607fcb0d7ebfd9c5dfb7bc04f5bd29a4bcf64b01c0fd8aeab54363,Yahoo,negative,0.9385
2025-03-26 18:00:00,"Strategically Building A $100,000 Dividend Portfolio For Attractive Income And Strong Risk-Adjusted Returns",The Dividend Income Accelerator Portfolio focuses on financially healthy companies with strong balance sheets. Check out the recent additions to the portfolio.,https://finnhub.io/api/news?id=ce462cc0e5b7f820a511093e525334e1bca7d2a89963f65cc3b58e557cad4636,SeekingAlpha,negative,0.8397
2025-03-26 16:37:29,Johnson & Johnson Reports Positive Data from Phase 3 Study of Lung Cancer Drug Candidate,Johnson & Johnson (JNJ) said Wednesday that results from a phase 3 trial showed that Rybrevant as a,https://finnhub.io/api/news?id=fff9a4556ed0e684ae8bf06d03fb9d9a07dd44160c30f0e8c2c26f5686009485,Yahoo,negative,0.9434
2025-03-26 15:45:00,RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer,Johnson & Johnson (NYSE:JNJ) today announced results for the gold standard endpoint in cancer treatment of overall survival (OS) from the Phase 3 MARIPOSA study. Head-to-head comparison data versus osimertinib showed RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) significantly extended OS in the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substi,https://finnhub.io/api/news?id=8338901da52e0f7881b5626f4504fc996e9cdf897d58f656d8d9eb808ae5dfb8,Yahoo,negative,0.9512
2025-03-26 13:40:10,Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock,"Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",https://finnhub.io/api/news?id=044da3b2d7cf3fd7d2abd605ab510c43cc86e0f5c03ee0dac248804e732ca3d4,Yahoo,positive,0.7714
2025-03-26 13:37:02,J&J Says Median Overall Survival Not Yet Reached With Projected Improvement Of More Than One Year Versus Osimertinib,Johnson & Johnson: * RYBREVANT® PLUS LAZCLUZE™ OUTPERFORMS OSIMERTINIB WITH A SIGNIFICANT AND UNPRECEDENTEDOVERALL SURVIVAL BENEFIT IN PATIENTS WITH EGFR-MUTATED NON-SMALLCELL...,https://finnhub.io/api/news?id=81a15a55e99dc1f9d1449fd8c8d363db69200415d668a689e6163daa5fb696bc,Finnhub,negative,0.9434
2025-03-26 13:00:05,These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar,The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.,https://finnhub.io/api/news?id=d9865ff417cd6034cf187b07246b2a5bfe33f68604f89ab29403651a4116fcfd,Yahoo,positive,0.764
2025-03-26 12:18:49,Johnson & Johnson MedTech introduces electrosurgical generator,The solution is designed for future compatibility with the company's Ottava Robotic Surgical System.,https://finnhub.io/api/news?id=61740b54647ac30793741d17d1c7ae5a6e4c332a4892573b49159f33e7354618,Yahoo,positive,0.7507
2025-03-26 12:03:00,New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG),"Johnson & Johnson (NYSE: JNJ) announced today that 12 abstracts, including two oral presentations, highlighting the Company's innovative autoantibody disease research and the potential of nipocalimab to provide long-term sustained disease control in the treatment of generalized myasthenia gravis (gMG), will be presented at the 2025 American Academy of Neurology (AAN) Annual Meeting from April 5 – 9 in San Diego, California.",https://finnhub.io/api/news?id=166d60ffe3b17a87acfe3371104d36a6f20eececace0cf78ede1695812f52854,Yahoo,negative,0.9245
2025-03-25 09:54:06,Johnson & Johnson : MedTech Launches the DUALTO™ Energy System for Use Across Surgical Treatment Approaches,"New Brunswick, NJ - March 25, 2025 - Johnson & Johnson MedTech, a global leader in surgical technologies and solutions, today announced the launch of the DUALTO™ Energy System, a surgical solution...",https://finnhub.io/api/news?id=8365a9e51b99003ddc01f599d129604bac98a87103556f60b02c1a7973c1aff2,Finnhub,positive,0.5465
